The way TRT is delivered has changed substantially in the last decade. Old protocols of 200mg intramuscular every two weeks are being replaced by small subcutaneous doses every two to three days, with steadier troughs, fewer side effects, and lower management burden. This post covers what modern TRT actually looks like — and where the dosing line sits between TRT, gym aesthetics, bodybuilding and powerlifting use. Honestly told.
The word "TRT" has become slippery. It now gets applied to everything from properly-supervised 100mg-per-week medical replacement to 500mg-per-week supraphysiological cycles. That's not pedantry — it matters, because the side-effect profile, the legal status, the cardiovascular signature and the fertility consequences are completely different across that range.
This piece does two things. First, it lays out what modern, evidence-based TRT actually looks like in 2026 — because the protocols most prescribers were trained on are now 10+ years out of date. Second, it draws an honest line between TRT and the supraphysiological dose ranges that get marketed as TRT but aren't. The categories matter, especially for younger men who are being sold cycles dressed up as medicine.
A 35-year-old man we work with started TRT after a morning serum total testosterone of 6 nmol/L — well below the lower NHS reference (around 8.4 nmol/L) and into the range where men get neurological symptoms. He was experiencing chronic dry eye and intermittent vision issues — meibomian gland dysfunction is testosterone-dependent — alongside connective tissue breakdown, persistent fatigue, recovery failure, and the general sense of "everything falling apart" that severe deficiency creates.
His current protocol: 50mg testosterone cypionate subcutaneously every 3 days. Steady-state total testosterone now sits at approximately 30 nmol/L, with no perceptible peaks or troughs between doses. He reports no day-to-day variation in energy, mood, or libido — the steadiness people associate with mid-physiological replacement when delivered correctly.
The main practical risk on this protocol is missing doses. Small frequent injections require consistency; a 24-hour delay matters more than it does on a once-weekly schedule. Reminders, prep routines, and pre-loaded syringes solve this for most users — but it's the part of modern TRT that's worth flagging honestly.
For decades, the default UK TRT protocol was intramuscular testosterone enanthate or cypionate, dosed every 2–3 weeks. The science behind that schedule was largely about depot kinetics — push a big dose into muscle, let it diffuse out over time. The problem is that "over time" turned out to mean a sharp peak in the first 48 hours followed by a long decline, with patients reliably feeling great for a week and progressively worse for the next two.
The shift began with Kaminetsky et al. 2018 (Journal of Sexual Medicine), demonstrating that subcutaneous testosterone enanthate produced comparable steady-state serum levels to intramuscular delivery at the same total weekly dose, with lower peak-to-trough variation. Multiple follow-up studies through 2022–2024 confirmed the same pattern with cypionate. The clinical implications:
Steadier oestradiol. Big peaks drive aromatisation. Small frequent doses keep oestradiol steadier, often eliminating the need for aromatase inhibitors entirely.
Lower haematocrit elevation. The erythropoietic stimulus correlates with peak rather than trough levels. Smaller peaks mean less haematocrit creep, and many men on SubQ EOD protocols stay below the 54% management threshold without phlebotomy.
Better mood stability. The "TRT roller-coaster" of feeling great early in the cycle and declining toward the end is largely a function of dose schedule, not the molecule. Frequent dosing flattens it.
Smaller needle, less pain. SubQ uses 27g–30g insulin needles in the subcutaneous fat of the abdomen or thigh. Intramuscular requires 23g–25g into the glute, quad or deltoid. The difference in injection burden is significant — particularly over years.
This is the shape of properly-supervised TRT in 2026. Doses below 100mg/week are insufficient for most hypogonadal men; doses above 200mg/week start moving into supraphysiological territory and warrant a different conversation.
Here's the framework the rest of the post hangs on. The doses, the goals, and the risk profiles diverge sharply across these four categories, even though the public conversation tends to lump them together as "test."
The line we draw on this platform: TRT is the medical replacement of a documented hormone deficiency. Above roughly 200mg/week, you are no longer replacing a deficiency — you are creating a state your body wouldn't naturally produce, for reasons unrelated to medicine. Both can be informed adult choices, but they are not the same choice.
This matters most for younger men. We see 21–28 year olds being told they're "on TRT" at 300–500mg/week, often by coaches with commercial incentives. They aren't. They're on a cycle. The endocrine, fertility and cardiovascular consequences they face are different to a 45-year-old hypogonadal man on 120mg/week — and pretending otherwise sets them up to make decisions on bad information.
Pep IQ documents what the evidence actually shows. The evidence on physiological TRT in genuinely deficient men is strong and overwhelmingly positive. The evidence on chronic supraphysiological dosing is sparser, longer-tailed, and includes more concerning signals — particularly around cardiac structure, lipid profile, and reversibility of HPG axis suppression. We don't tell adults what to do. We do tell them honestly which category they're actually in.
Pre-treatment: total testosterone, free testosterone, SHBG, oestradiol (sensitive assay), LH, FSH, prolactin, full blood count, lipid panel, hsCRP, PSA (over 40), HbA1c. Six weeks after starting: re-check total T, oestradiol, haematocrit. Stable: every 6 months.
Gonadorelin or HCG to preserve testicular function and fertility. Aromatase inhibitor (anastrozole) only if oestradiol is genuinely high and symptomatic — chasing the number alone causes more problems than it solves. Most men on modern frequent-dose protocols don't need an AI.
Small frequent injection schedules require consistency. Missing a dose by 24 hours doesn't ruin treatment, but missing repeatedly creates the same instability the protocol was designed to avoid. The practical solution is a fixed routine — same time of day, prepped supplies, calendar reminders, doses logged. The Pep IQ Tracker handles this automatically and flags missed days. Whatever system you use, build one before you start.
TRT doesn't fix everything attributed to it. Persistent fatigue, depression, or low libido that don't resolve on optimal levels suggest something else is going on — sleep apnoea, thyroid dysfunction, gut health, mental-health issues, a relationship that's the actual problem. Replacing testosterone fixes testosterone deficiency. It doesn't fix the rest of life.
The 35-year-old described earlier is now ~24 months into his protocol. Total testosterone steady at ~30 nmol/L. Oestradiol mid-range without an AI. Haematocrit stable at ~50% on EOD SubQ. Vision restored. Connective tissue rebuilt over the first 12–18 months — old injuries that hadn't healed for years are no longer symptomatic. Energy and recovery are at the levels he had in his early 20s. Bloods are reviewed every 6 months and have been unremarkable beyond the targeted changes.
His prescribing physician is a TRT specialist working from current evidence. The protocol is monitored. The lifestyle work alongside it — sleep, training, nutrition, stress management — is doing the other 50% of the lifting that TRT alone would not do. That combination is what works. TRT in isolation, on top of a fundamentally broken lifestyle, doesn't.
If you have testosterone of 6 nmol/L and your life is falling apart, TRT is medicine and the data on properly-managed replacement is reassuring. If you have testosterone of 18 nmol/L and you want bigger arms, you may end up benefiting from supraphysiological doses but you are not doing TRT — and the risk-benefit conversation is genuinely different. Both are adult decisions. But they should be made knowing which one is which.
That's the position. That's why Pep IQ exists in the form it does — to document what the evidence actually shows, including the parts other platforms gloss over because they are less commercially convenient.
We'll email you when we publish something new. Free, no account needed, unsubscribe anytime.
Full TRT blood work calendar, gonadorelin protocol, peptide companion guide, and the Tracker that flags missed doses — available to members.